Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617388 | 0.85 | ALDH1A1 (0.46) | NQO2MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL1615754 | 0.85 | ALDH1A1 (0.46) | NQO2MAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2905353 | 0.84 | NQO2 (0.56) | NQO2KDM4EALDH1A1MRGPRX4 | |
| SCHEMBL9462823 | 0.84 | NQO2 (0.75) | NQO2ABL1KDM4EMRGPRX4 | |
| SCHEMBL9391555 | 0.82 | NQO2 (0.40) | NQO2KMT2A | |
| SCHEMBL9462760 | 0.82 | NQO2 (0.64) | NQO2KDM4E | |
| SCHEMBL9463012 | 0.82 | NQO2 (0.64) | NQO2KDM4EALDH1A1MRGPRX4 | |
| SCHEMBL8946290 | 0.82 | NQO2 (0.53) | NQO2KDM4EALDH1A1MRGPRX4 | |
| SCHEMBL9462812 | 0.76 | NQO2 (0.64) | NQO2KDM4EMAPTKMT2A | |
| SCHEMBL14743306 | 0.75 | NQO2 (0.48) | NQO2ALDH1A1MRGPRX4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | LOHOCLA RESEARCH CORPORATION (US) | 2021-09-28 | — | — | US | disclosed |
| US-10435371-B2 | Multifunctional aminoquinoline therapeutic agent | LOHOCLA RESEARCH CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-10391088-B2 | Analgesic compositions | LOHOCLA RESEARCH CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | LOHOCLA RESEARCH CORPORATION | 2019-04-04 | — | — | US | disclosed |
| US-20190092731-A1 | MULTIFUNCAIONAL AMINOQUINOLINE THERAPEUTIC AGENT | LOHOCLA RESEARCH CORPORATION | 2019-03-28 | — | — | US | disclosed |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2017-07-20 | — | — | US | disclosed |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION | 2017-07-20 | — | — | US | disclosed |
| WO-2015195943-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | LOHOCLA RESEARCH CORPORATION (US) | 2015-12-23 | — | — | WO | disclosed |
| US-5493027-A | ANTIEPILEPTIC AGENTS, NEUROGENATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-02-20 | — | — | US | disclosed |
| WO-1994017042-A1 | ANTICONVULSIVE AGENTS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | OPRK1, OPRM1, OPRD1 | NQO2 84/4885ABL1 38/4885KDM4E 1097/4885 |
| US-10391088-B2 | Analgesic compositions | OPRK1, OPRL1, OPRM1 | NQO2 742/4885ABL1 1926/4885KDM4E 3189/4885 |
| US-20190099412-A1 | ANALGESIC COMPOSITIONS | OPRK1, OPRL1, OPRM1 | NQO2 742/4885ABL1 1926/4885KDM4E 3189/4885 |
| US-20190092731-A1 | MULTIFUNCAIONAL AMINOQUINOLINE THERAPEUTIC AGENT | OPRK1, OPRL1, PNMT | NQO2 48/4885ABL1 49/4885KDM4E 1720/4885 |
| US-20170204064-A1 | MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS | OPRK1, OPRM1, OPRD1 | NQO2 82/4885ABL1 50/4885KDM4E 1838/4885 |
| US-10435371-B2 | Multifunctional aminoquinoline therapeutic agent | OPRK1, OPRM1, OPRD1 | NQO2 92/4885ABL1 53/4885KDM4E 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.